Recent research published in Frontiers in Immunology brings promising news for multiple myeloma (MM) patients undergoing maintenance therapy. The study demonstrates that while these patients may produce fewer antibodies, their T-cell response following SARS-CoV-2 vaccination mirrors that of healthy individuals, offering crucial protection against COVID-19.
T-Cell Response Findings
The research, conducted between May 2022 and October 2023, compared immune responses in 41 MM patients receiving lenalidomide maintenance therapy with 43 healthy controls. Notably, MM patients exhibited superior T-cell responses compared to controls, regardless of previous COVID-19 infection status (spike protein activated: P = .0076; nucleocapsid protein activated: P = .043).
These findings are particularly significant given that MM patients typically face increased vulnerability to infections due to compromised immune systems resulting from their treatment regimens. The study revealed that MM patients who had previously contracted COVID-19 demonstrated even stronger T-cell responses compared to controls with similar infection history (N activated: P = .03).
Patient Demographics and Treatment Details
The MM patient cohort, with an average age of 64 years, predominantly consisted of individuals in complete serological remission (73%). The majority (82.9%) were actively receiving daily lenalidomide, with an average treatment duration of 4.7 years. All patients had received immunomodulatory drug-based treatment and proteasome inhibitors as part of their therapy.
Vaccination rates were high in both groups, with 92.6% of MM patients and 93% of controls having received COVID-19 vaccines. MM patients received more vaccine doses on average compared to controls (median of 4 vs 3; P < .001).
Implications for Clinical Practice
While healthy controls demonstrated more robust antibody responses (N IgA levels: P < .001), the strong T-cell response in MM patients suggests that vaccination remains a crucial protective measure for this vulnerable population. Importantly, the study found no negative impact on immune response whether patients continued or temporarily suspended lenalidomide treatment around vaccination time.
"This outcome showcases the importance of vaccination in MM patients and moreover, our results argue against a lenalidomide break around the time of vaccination," the researchers noted, emphasizing the significance of T cell-based vaccine responses in immunocompromised patients.
Treatment Context
Lenalidomide, approved by the FDA in 2017 for maintenance treatment in MM following autologous stem cell transplant, functions as an immunomodulatory drug. The medication's potential stimulatory effect on immune cells may contribute to the observed robust T-cell responses, though further research is needed to fully understand this relationship.
These findings provide valuable insights for healthcare providers managing MM patients during the ongoing COVID-19 pandemic, suggesting that maintaining vaccination schedules while continuing lenalidomide therapy may offer optimal protection for this high-risk population.
